The research, led by Penghui Song, Lijuan Ma, and Dong Yan and published in PLOS Genetics, set out to answer a deceptively simple question: what does Mettl16 actually do in Drosophila melanogaster? In mammals, METTL16 is essential for embryonic development, and its loss is lethal, largely because it modifies a specific structural RNA involved in splicing and helps regulate the synthesis of S-adenosylmethionine, the universal methyl donor of the cell. Because flies lack some of the mammalian regulatory features, the expectation was that Mettl16 might behave similarly, or perhaps be dispensable altogether. The team generated flies carrying loss-of-function mutations in the Mettl16 gene and watched what happened across the entire life cycle. The result was unexpected: unlike in mammals, Mettl16 mutant flies survived to adulthood. They were alive, but far from well, displaying a constellation of developmental and behavioral abnormalities that hinted at a deep, if selective, importance of this enzyme.

The most dramatic phenotype was sterility. Both male and female mutants were completely infertile, and microscopic examination of their gonads revealed severe defects in gametogenesis, the intricate choreography by which germ cells divide, specialize, and mature into sperm and eggs. This was a crucial clue. Fertility is one of the most sensitive readouts of RNA metabolism, because germ cells undergo some of the most dramatic transcriptional and developmental transitions in any tissue. The fact that Mettl16 loss brought the entire reproductive program to a grinding halt suggested that the enzyme supports specific, non-redundant steps in the formation of gametes, rather than serving as a general housekeeping factor that cells could easily compensate for.

To pinpoint where things went wrong, the researchers traced germ cell development stage by stage. Remarkably, Mettl16 mutant germ cells were able to navigate the early milestones without obvious catastrophe: they completed the mitotic divisions that expand the germline population and progressed through meiosis, the specialized reductional division that generates haploid cells. The breakdown came later, during spermiogenesis, the transformation of round spermatids into the sleek, elongated, motile sperm that define male fertility. In the mutants, spermatid elongation faltered and individualization, the process by which each spermatid is sculpted, compacted, and encased in its own membrane sheath, failed to proceed properly. This stage-specific failure is telling, because spermatid elongation and individualization demand massive, precisely timed remodeling of the cytoskeleton, of chromatin, and of RNA populations inherited from earlier stages. Mettl16 therefore appears to be required for the late maturation program of sperm rather than for the fundamental mechanics of cell division.

Where does the enzyme live inside the cell, and what does it do when it gets there? The team tagged Mettl16 with green fluorescent protein and found that the fusion protein localized predominantly to the nucleus, consistent with a role in nuclear RNA processing rather than in the cytoplasmic control of translation. To test whether Mettl16 loss broadly crippled protein synthesis, the researchers examined wing disc epithelial cells, a classic Drosophila model tissue, and found that global protein production was not impaired in the absence of the enzyme. This observation carries real weight. If Mettl16 were a major regulator of mRNA translation, its removal should have left a visible signature on the protein output of the cell. Instead, the data pointed toward a narrower, more targeted function, in which only a specific set of RNA substrates depends on Mettl16 activity.

That selectivity was confirmed at the level of the transcriptome-wide methylome. Using MeRIP-Seq, a technique that immunoprecipitates methylated RNA fragments and maps them back to the genome, the researchers compared the m6A landscape of normal flies with that of Mettl16 mutants. The comparison produced a striking contrast. When Mettl3 is lost, the effect on m6A is broad, sweeping away the modification from a large fraction of transcripts across the transcriptome. Mettl16 loss, by comparison, altered m6A on only a small subset of RNAs. This result reframes the two enzymes as complementary writers with distinct substrate preferences: Mettl3 acts as the bulk methyltransferase decorating thousands of messages, while Mettl16 behaves as a specialist, placing marks on a curated list of targets whose identity appears central to the phenotypes observed in the mutant flies.

Among those targets, one stood out with particular clarity: U6 snRNA, the small nuclear RNA that forms the catalytic heart of the spliceosome, the molecular machine that removes intervening sequences from pre-messenger RNAs. The team demonstrated that Mettl16 physically interacts with U6 snRNA and is required for its m6A modification. This finding connects the fly enzyme to one of the most conserved functions described for METTL16 in other organisms, the methylation of U6, and it immediately suggested a mechanism by which the enzyme could exert widespread downstream effects. Splicing is the process that stitches together the coding segments of genes, and alternative splicing allows a single gene to produce multiple protein variants. If Mettl16 fails to methylate U6, the spliceosome’s precision could be subtly compromised, reshuffling the splicing patterns of many genes even though only a handful of transcripts lose their m6A marks directly.

That prediction held up. The researchers found that Mettl16 mutants display widespread alterations in alternative splicing, meaning that the way numerous pre-messenger RNAs are assembled into mature messages changes throughout the animal. This splicing dysregulation provides a plausible mechanistic bridge between the enzyme’s narrow biochemical footprint and its pleiotropic developmental consequences. Genes required for spermatid elongation, for oogenesis, and for normal behavior could each be mis-spliced in the mutant, producing protein isoforms that are truncated, unstable, or functionally altered. The picture that emerges is one of indirect amplification: a single, targeted RNA modification on a core splicing component ripples outward into broad changes in gene expression, which in turn manifest as the sterile, behaviorally abnormal flies observed in the study.

The evolutionary implications of the work are equally compelling. Comparing flies with mammals reveals a remarkable divergence in biological logic. In mammals, METTL16 is indispensable, its loss lethal during embryogenesis, whereas in flies the enzyme is dispensable for viability but essential for reproduction and normal development. This kind of comparative data helps researchers understand how the epitranscriptome has been rewired across hundreds of millions of years of evolution, with the same chemical modification and the same family of writer enzymes being deployed in different tissues and at different developmental checkpoints depending on the organism. It also cautions against assuming that findings from one model system translate directly to another, a lesson with practical consequences for biomedical research that relies on m6A biology as a therapeutic target.

For the growing community of scientists studying RNA modifications, the Drosophila study adds an important piece to the puzzle of how m6A writers divide their labor. Mettl3 emerges as the generalist, methylating a broad swath of the transcriptome, while Mettl16 operates as a specialist whose most clearly defined substrate is the U6 snRNA at the heart of the splicing machinery. The pleiotropic phenotypes of Mettl16 mutants, from failed spermatid individualization to behavioral defects, most likely stem from the combination of direct m6A deposition on specific target transcripts and the indirect consequences of U6-dependent splicing regulation. As epitranscriptomics moves from cataloging modifications toward understanding their causal roles in development and disease, this fly work demonstrates that even a small subset of methylated RNAs, when left unmodified, can be enough to derail some of the most elaborate programs an animal ever runs, including the construction of the next generation itself.

Subject of Research: The role of the m6A methyltransferase Mettl16 in Drosophila development, fertility, and RNA splicing regulation

Article Title: Role of the m 6 A methyltransferase Mettl16 in Drosophila development

Article References: Song, P., Ma, L., & Yan, D. (2026). Role of the m6A methyltransferase Mettl16 in Drosophila development. PLOS Genetics, 22(9), e1012317. https://doi.org/10.1371/journal.pgen.1012317

Image Credits: AI Generated

DOI: 10.1371/journal.pgen.1012317

Keywords: m6A, Mettl16, Drosophila, epitranscriptomics, RNA methylation, U6 snRNA, alternative splicing, gametogenesis, spermatid individualization, PLOS Genetics, methyltransferase, developmental biology

The original article, published on 23 January 2017 by a team at the Department of Oncology of the First Affiliated Hospital of Nanchang University in China, reported that miR-511, a short non-coding RNA, could influence the behavior of gastric cancer cells by targeting TRIM24, a protein belonging to the tripartite motif family of E3 ubiquitin ligases. The paper was part of a broader wave of research into microRNAs, the roughly 20 to 24 nucleotide RNA fragments that fine-tune gene expression after transcription and have been implicated in nearly every aspect of tumor biology, from proliferation and invasion to resistance against chemotherapy. For a cancer as difficult to treat as gastric cancer, which remains among the leading causes of cancer death worldwide, any molecular handle on cell proliferation seemed worth pursuing.

The first problem identified by the retraction note concerns how the microRNA measurements were normalized, a step that is deceptively simple but absolutely critical to the validity of quantitative PCR experiments. When scientists measure the abundance of a microRNA, they do so relative to a reference molecule whose levels are assumed to remain stable across all samples and conditions. The original paper stated that microRNA results were normalized to U6 snRNA, a small nuclear RNA that has long served as a conventional, if sometimes controversial, reference in microRNA studies. The trouble, according to the retraction, is that the primers actually used in the experiments did not amplify U6 at all. Instead, they amplified the messenger RNA of LSM5, a protein-coding gene involved in RNA splicing.

That distinction matters far more than it might first appear. U6 snRNA is a small, abundant, non-coding RNA whose expression is generally treated as constitutive, which is precisely why it became a default reference in the microRNA field. LSM5, by contrast, is a messenger RNA encoding the Sm-like protein 5, a component of the spliceosomal machinery, and there is no reason to expect its levels to remain constant across cancer cell lines, treatments, or experimental manipulations. If LSM5 expression happened to shift between the compared groups, every downstream calculation of relative microRNA abundance would be skewed, potentially producing apparent differences in miR-511 levels that were nothing more than artifacts of a moving baseline. The retraction note states plainly that the normalization procedure described is incorrect and that the conclusions based on these data cannot be considered reliable.

Primer specificity errors of this kind are more common than many researchers would like to admit. In quantitative reverse transcription PCR, the design of primers determines which molecule in a complex cellular extract gets amplified and measured. A primer set intended for one RNA species can, if misdesigned, misordered, or mislabeled, silently target another. When the mistake goes undetected, the resulting fold-change values can look perfectly plausible, pass peer review, and enter the literature as apparently solid findings. It is often only years later, when readers scrutinize the methods, request the primer sequences, or attempt to replicate the results, that the discrepancy surfaces. In this case, the retraction indicates that concerns were raised after publication, prompting the editorial investigation that ultimately led to the withdrawal.

The second pillar of the retraction is arguably even more consequential for the wider cancer research community. The retraction note reports that the BGC823, MGC803, and SGC7901 cell lines used in the study have been reported to be contaminated with HeLa cervical cancer cells, rendering them unsuitable as models of gastric cancer. HeLa, the immortal cell line derived from Henrietta Lacks in 1951, is the most notorious cross-contaminant in laboratory biology. Its aggressive growth and remarkable robustness have allowed it to overtake and displace the original cells in countless cultures around the world, often without the researchers knowing. An experiment performed on what is labeled as a gastric cancer line but is actually dominated by HeLa cells is, in effect, an experiment on cervical cancer cells wearing a false label.

Cell line misidentification and cross-contamination have plagued biomedical research for decades, and estimates of the fraction of published studies using problematic lines run disturbingly high. Authentication of cell lines through short tandem repeat profiling, a technique that fingerprints the genetic identity of a culture, is now demanded by many journals and funding agencies precisely because of cases like this one. The three lines implicated in the retracted paper have appeared in hundreds of publications over the years, and their compromised status has been documented in registries of misidentified cell lines. Yet they continue to circulate in laboratories, often passed along between groups with the assumption that a vial labeled BGC823 or SGC7901 contains what the label says. The retraction serves as a fresh reminder that a cell line’s provenance must be verified, not presumed.

The combination of the two failures is what makes the retraction unavoidable from a scientific standpoint. Even if the microRNA measurements had been correctly normalized, the biological conclusions would still rest on cells that were not what the authors believed them to be. Conversely, even authentic gastric cancer cells could not have rescued a dataset whose reference gene was misidentified. The Editor-in-Chief concluded that confidence in the data could not be maintained, and the article was retracted accordingly. The retraction note also records the human dimension of the process: authors Ziling Fang, Jianping Xiong, and Xiaojun Xiang agreed with the retraction, while the remaining authors did not respond to correspondence regarding it. Such partial responses are common in retraction cases and often reflect the difficulty of reaching co-authors years after the original work was completed.

For the field of gastric cancer biology, the retraction removes one data point from a crowded literature on microRNA regulation of TRIM24, but it does not necessarily invalidate the broader hypothesis that miR-511 or related microRNAs influence TRIM24 expression in gastrointestinal tumors. TRIM24 has been independently implicated in multiple cancers as an oncogenic regulator that links chromatin remodeling with hormone signaling and degradation of tumor suppressors, and microRNA control of TRIM24 has been reported by other groups using different models and methods. The distinction that matters is between a hypothesis, which may well survive, and a specific dataset, which can no longer be trusted or cited as evidence. Researchers building on the 2017 paper will now need to look to studies performed with authenticated cell lines and verifiable normalization schemes.

The episode also illustrates how the machinery of research integrity works in practice. Concerns raised after publication are evaluated by journal editors, sometimes with input from institutional investigators, and when the evidence shows that the foundations of a paper are unsound, retraction follows regardless of the authors’ intentions. Errors of this kind, a mislabeled primer and contaminated cultures, may be honest mistakes rather than deliberate misconduct, but the scientific record cannot distinguish between them when the data themselves are unreliable. Retraction is the mechanism by which the literature corrects itself, ensuring that clinicians and researchers who search for evidence on miR-511 and TRIM24 are not misled by findings that cannot stand. For laboratories still working with BGC823, MGC803, or SGC7901, the message is unambiguous: authenticate your cells, verify your primers, and treat every reference gene as a hypothesis to be tested rather than a convention to be trusted.

Subject of Research: Retraction of a gastric cancer study on miR-511 regulation of TRIM24 due to qPCR normalization errors and HeLa-contaminated cell lines

Article Title: Retraction Note: Regulation of TRIM24 by miR-511 modulates cell proliferation in gastric cancer

Article References: Zhang, L., Liao, Q., Wang, Y., Yu, F., Feng, M., Xiang, X., & Xiong, J. (2026). Retraction Note: Regulation of TRIM24 by miR-511 modulates cell proliferation in gastric cancer. Journal of Experimental & Clinical Cancer Research, 45(1), Article 206. https://doi.org/10.1186/s13046-026-03838-9

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03838-9

Keywords: gastric cancer, retraction, miR-511, TRIM24, microRNA, U6 snRNA, LSM5, HeLa contamination, cell line misidentification, qPCR normalization, BGC823, research integrity

Inherited retinal dystrophies are a leading cause of irreversible blindness worldwide, and retinitis pigmentosa, the most common form, affects an estimated 2.5 million people. More than 100 causative genes have been identified, yet between 30 and 50 percent of cases still lack a genetic diagnosis, and the observation of incomplete penetrance hints that factors beyond DNA sequence are at work. Epigenetic mechanisms, which modulate gene expression without altering the genome, have increasingly come into focus in ocular disease. Among these, m6A stands out as the most abundant internal modification in eukaryotic messenger RNA, deposited by writer enzymes, removed by erasers such as FTO and ALKBH5, and interpreted by reader proteins that influence splicing, export, stability, and translation.

METTL16 is a relative newcomer to the m6A field. Unlike the well-known METTL3/METTL14 complex, it recognizes a specific motif, UACAGARAA, within structured RNA contexts, and its validated substrates include MAT2A mRNA, which it regulates to maintain cellular levels of the universal methyl donor S-adenosylmethionine, and U6 snRNA, a small nuclear RNA at the heart of the splicing machinery. METTL16 methylates U6 at position A43 within the ACAGAGA sequence that base-pairs with the 5′ splice site of introns during pre-mRNA splicing. Work in fission yeast, roundworms, plants, and human cells has shown that losing this modification impairs 5′ splice site recognition. Intriguingly, dominant mutations in U6 snRNA have recently been linked to autosomal dominant retinitis pigmentosa, and those variants cluster in regions that contact spliceosome components such as PRPF3, PRPF8, and PRPF31, proteins that are themselves mutated in RP.

To probe METTL16’s role in the retina, the team, led by Jiangbo Ren, Wenjing Liu, and colleagues, generated rod-specific Mettl16 knockout mice by crossing Mettl16-floxed animals with RHO-Cre mice, in which the recombinase is active only in rods. The resulting RKO mice showed efficient excision of the targeted exon and a marked reduction of METTL16 protein in the retina. Single-cell RNA sequencing data from the Human Protein Atlas had already indicated that METTL16 is broadly expressed across retinal cell types, with notable enrichment in rods, making the knockout strategy well suited to testing its function in the cells most vulnerable to retinitis pigmentosa.

The physiological consequences were swift and measurable. Electroretinograms recorded at one month of age revealed that scotopic responses, which reflect rod function, were severely blunted: a-wave and b-wave amplitudes were reduced by roughly 54 and 55 percent, respectively, compared with littermate controls. Cone-mediated photopic responses, by contrast, were largely preserved at this stage, pointing to a rod-first pattern of degeneration. Behavioral assays corroborated the electrophysiology. In a light-dark box test, RKO mice spent only about 39 percent of their time and traveled about 42 percent of their distance in the dark chamber, unlike control mice, which normally prefer darkness. Their optomotor response, a reflexive head movement that tracks rotating visual gratings, dropped to 1.56, well below the values of 2.0 or higher seen in controls.

Under the microscope, the story continued. At postnatal day 20, retinal architecture looked normal, but by day 30 the outer nuclear layer and outer segments of RKO retinas were visibly thinning, and by day 40 the outer nuclear layer had lost roughly 40 percent of its thickness relative to controls. Immunofluorescence showed that key outer segment proteins, including rhodopsin, PRPH2, GRK1, PDE6B, and CNGA1, were markedly reduced in abundance even though their localization within the photoreceptor was not disrupted. Signs of degenerative stress were everywhere: Müller glia became reactive, microglia adopted an amoeboid morphology and invaded the outer nuclear layer, and TUNEL staining detected apoptotic nuclei among the photoreceptors. Cones, meanwhile, showed only delayed involvement, with reduced M-opsin-positive cells appearing by day 40.

To trace the molecular roots of this collapse, the researchers integrated RNA sequencing with quantitative proteomics on one-month-old retinas. Among the genes concordantly downregulated at both the transcript and protein levels, Gene Ontology and KEGG analyses pointed squarely at photoreceptor development, photoreceptor cilia, inner and outer segments, visual perception, and the phototransduction cascade. Five established retinitis pigmentosa genes emerged from this analysis: Tulp1, Cnga1, Pde6g, Crb1, and Prcd. Four of them showed significant differential expression at both levels after correction for multiple testing, and the reductions were confirmed by RT-qPCR and Western blotting. The metabolic arm of the analysis revealed perturbations in the S-adenosylmethionine pathway as well, with Mat2a mRNA, a direct METTL16 substrate, reduced in knockout retinas, and Csad, a key enzyme of taurine biosynthesis, markedly decreased.

The mechanistic core of the paper lies in splicing. Using a single-base elongation and ligation-based qPCR assay called SELECT on purified U6 snRNA, the team confirmed that m6A at position A43 was reduced in knockout retinas. Transcriptome-wide analysis with rMATS then revealed extensive alternative splicing changes, with skipped exons as the predominant event class. Sequence analysis of affected 5′ splice sites showed a telling pattern: sites whose usage decreased in knockout retinas were enriched for adenosine at the +4 position, the very nucleotide engaged by methylated U6, and carried an RAG motif across the U6-interacting positions, whereas sites with increased usage favored stronger U5 snRNA base pairing and non-adenine nucleotides at +4. Crucially, aberrant splicing was already detectable at postnatal day 20, before any overt cell loss. Both Tulp1 and Pde6g, two established retinal dystrophy genes, showed increased exon skipping, and the affected donor sites shared the conserved //GURAG motif previously implicated in METTL16 loss in plants and worms. MeRIP-seq showed no change in m6A enrichment on the Tulp1 and Pde6g transcripts themselves, consistent with a U6-dependent mechanism rather than direct methylation of the mRNAs. The Tulp1 exon 4-skipped transcript is predicted to encode an in-frame deletion of 51 amino acids, and immunostaining revealed disrupted ribbon synapse architecture in knockout retinas, echoing the synaptic defects known from Tulp1 knockout mice.

The study also documented METTL16’s influence beyond the nucleus. MeRIP-seq identified Tor1b and Nlgn2 as candidate direct m6A targets, with reduced methylation in their 3′ untranslated regions and reduced expression in knockout retinas; luciferase reporter assays showed that wild-type METTL16 enhanced reporters bearing the wild-type 3′ UTRs but not motif-mutated versions, and a catalytic-domain-deficient METTL16 mutant failed to do so. In photoreceptor-derived 661W cells, loss of METTL16 accelerated the decay of both transcripts, indicating effects on mRNA stability. Meanwhile, immunoprecipitation coupled with mass spectrometry revealed that retinal METTL16 associates with translation factors including PURA, PABPC1, and EIF3B, and with the splicing factors SF3B1 and SF3B3. SUnSET assays and polysome profiling showed that Mettl16 knockdown reduced global translation efficiency in 661W cells, and polysome analysis confirmed diminished translational efficiency of phototransduction genes such as Cep164, Rpgr, Prph2, and Cnga1, whose mRNA levels were unchanged even as their proteins declined.

The authors are careful to note the limitations: most molecular analyses used bulk retinal tissue, which can blur cell-type-specific effects and mix primary METTL16-dependent events with secondary degenerative changes, and the mechanistic work relied on the 661W cell line because mature rods are difficult to manipulate in vitro. Catalytically dead rescue experiments and ribosome profiling will be needed to determine whether the translational role depends on methyltransferase activity. Even so, the picture that emerges is striking. METTL16, working in both the nucleus and the cytoplasm, appears to safeguard photoreceptors on at least three fronts: by methylating U6 snRNA to preserve splicing fidelity in dystrophy genes, by stabilizing specific m6A-marked transcripts, and by supporting the translation of the proteins that build the light-sensing machinery. Given that mutations in U6 snRNA and multiple spliceosome components cause retinitis pigmentosa in humans, the study suggests that RNA processing defects may be a broader and previously underappreciated theme in photoreceptor disease, one that could eventually inform diagnostic and therapeutic strategies for the many patients whose blindness still has no genetic explanation.

Subject of Research: The role of the m6A methyltransferase METTL16 in photoreceptor survival and retinal degeneration

Article Title: METTL16 maintains photoreceptor integrity via splicing fidelity, mRNA stability, and translational regulation

Article References: Ren, J., Liu, W., Zou, R., Sun, K., Yang, M., Zhu, X., & Yang, Z. (2026). METTL16 maintains photoreceptor integrity via splicing fidelity, mRNA stability, and translational regulation. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2026.09.012

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.09.012

Keywords: METTL16, m6A, photoreceptors, retinitis pigmentosa, U6 snRNA, alternative splicing, RNA methylation, retinal degeneration, translation regulation, Tulp1, Pde6g, epitranscriptomics